CA2797444A1 - Solid oral dosage forms comprising tadalafil - Google Patents

Solid oral dosage forms comprising tadalafil Download PDF

Info

Publication number
CA2797444A1
CA2797444A1 CA2797444A CA2797444A CA2797444A1 CA 2797444 A1 CA2797444 A1 CA 2797444A1 CA 2797444 A CA2797444 A CA 2797444A CA 2797444 A CA2797444 A CA 2797444A CA 2797444 A1 CA2797444 A1 CA 2797444A1
Authority
CA
Canada
Prior art keywords
dosage form
tadalafil
polyoxyethylene
esters
acetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2797444A
Other languages
English (en)
French (fr)
Inventor
Horst Zerbe
Nadine Paiement
Angela Angusti
Cormac Long
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nualtis Corp
Original Assignee
IntelGenx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IntelGenx Corp filed Critical IntelGenx Corp
Publication of CA2797444A1 publication Critical patent/CA2797444A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2797444A 2010-04-26 2011-04-22 Solid oral dosage forms comprising tadalafil Abandoned CA2797444A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32796910P 2010-04-26 2010-04-26
US61/327,969 2010-04-26
US13/079,348 US20110263606A1 (en) 2010-04-26 2011-04-04 Solid oral dosage forms comprising tadalafil
US13/079,348 2011-04-04
PCT/IB2011/000882 WO2011135426A1 (en) 2010-04-26 2011-04-22 Solid oral dosage forms comprising tadalafil

Publications (1)

Publication Number Publication Date
CA2797444A1 true CA2797444A1 (en) 2011-11-03

Family

ID=44816306

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2797444A Abandoned CA2797444A1 (en) 2010-04-26 2011-04-22 Solid oral dosage forms comprising tadalafil

Country Status (5)

Country Link
US (2) US20110263606A1 (enExample)
EP (1) EP2563346A4 (enExample)
JP (1) JP2013527164A (enExample)
CA (1) CA2797444A1 (enExample)
WO (1) WO2011135426A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
GB2497728A (en) 2011-12-14 2013-06-26 Londonpharma Ltd Statin formulations for transmucosal delivery
GB2497933B (en) * 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
WO2013109221A1 (en) * 2012-01-18 2013-07-25 Mahmut Bilgic New effervescent formulations comprising sweetener composition
WO2013109230A1 (en) * 2012-01-18 2013-07-25 Mahmut Bilgic Pharmaceutical compositions comprising tadalafil
WO2014027975A2 (en) * 2012-08-17 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Novel orally administered pharmaceutical formulations
US20150320677A1 (en) * 2012-08-17 2015-11-12 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Effervescent tablet formulations of dapoxetine and a pde5 inhibitor
WO2014027980A1 (en) * 2012-08-17 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Oral film formulations comprising dapoxetine and tadalafil
WO2014027982A2 (en) * 2012-08-17 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Novel effervescent sachet formulations of dapoxetine and a pde5 inhibitor
BR112015025859A2 (pt) * 2013-04-11 2017-07-25 Ctc Bio Inc forma de dosagem de filme contendo base livre de tadalafila contendo polímero à base de polietilenoglicol e/ou polímero à base de vinilpirrolidona como estabilizador de dispersão
US11116769B2 (en) 2013-04-11 2021-09-14 Ctc Bio, Inc. Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer
KR102239291B1 (ko) * 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
HK1222796A1 (zh) * 2013-07-31 2017-07-14 因特根克斯公司 不含表面活性剂或多元醇的即时可湿性口服薄膜剂型
KR20150138671A (ko) * 2014-06-02 2015-12-10 에스케이케미칼주식회사 타달라필을 함유하는 구강 붕해 필름 및 이의 제조방법
ES2699160T3 (es) * 2014-06-24 2019-02-07 Wooshin Labottach Co Ltd Formulación de película de desintegración oral que contiene tadalafilo y procedimiento de preparación de la misma
KR101538985B1 (ko) * 2014-09-02 2015-07-24 주식회사 서울제약 타다라필 구강붕해필름 및 이의 제조방법
US20190133925A1 (en) 2016-03-11 2019-05-09 Intelgenx Corp. Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists
CZ2016570A3 (cs) * 2016-09-15 2018-03-28 Zentiva, K.S. Stabilní kompozice ODF obsahující těžce rozpustné terapeutické činidlo
CZ2017781A3 (cs) * 2017-12-05 2019-06-12 Zentiva, K.S. Těžko rozpustné terapeutická činidla,která patřící do BCS skupiny II nebo IV, suspendovaná v kapalné formulaci a/nebo v konečné nanovláknité struktuře
US20210137919A1 (en) * 2018-02-07 2021-05-13 Smawa Gmbh Pharmaceutical formulations, method for producing a pharmaceutical formulation, and medicament comprising same
CN109157520B (zh) * 2018-09-07 2021-04-02 苏州科技城医院 他达拉非片剂及其制备方法
US10828254B2 (en) 2018-09-28 2020-11-10 Intelgenx Corp. Oral film formulation for modulating absorption profile
US12303501B2 (en) 2018-11-05 2025-05-20 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
US12440472B2 (en) 2021-06-16 2025-10-14 Intelgenx Corp. Stable tryptamine oral films
US12648905B2 (en) 2022-01-19 2026-06-09 Intelgenx Corp. Oral films with flavor entrapment
WO2023232215A1 (en) * 2022-06-02 2023-12-07 Rontis Hellas S.A. Improved pharmaceutical composition containing tadalafil and process for the preparation thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
SV2002000055A (es) * 1999-04-30 2002-07-03 Lilly Icos Llc Articulos de manufactura ref. n0. 29342/36212 sv
JP2008546786A (ja) * 2005-06-23 2008-12-25 シェーリング コーポレイション Ｐｄｅ５インヒビターの迅速吸収性経口処方物
PL1948615T3 (pl) * 2005-11-08 2012-04-30 Pfizer Ltd Pochodne pirazolu przydatne w leczeniu chorób ginekologicznych
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
US20080009502A1 (en) * 2006-07-07 2008-01-10 Access Business Group International Llc Tadalafil solid composites
ES2405787T3 (es) * 2007-04-25 2013-06-03 Teva Pharmaceutical Industries Ltd. Formas de dosificación solidas
US20080292683A1 (en) * 2007-05-24 2008-11-27 Monosolrx, Llc. Film shreds and delivery system incorporating same
DE102007028869A1 (de) * 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
US20090047330A1 (en) * 2007-08-17 2009-02-19 Ramesh Bangalore Oral fast dissolving films for erectile dysfunction bioactive agents
MX2010004265A (es) * 2007-10-19 2010-07-28 Innozen Inc Composicion para administrar un ingrediente activo y metodo para hacer y usar el mismo.
KR101074271B1 (ko) * 2009-06-25 2011-10-17 (주)차바이오앤디오스텍 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름

Also Published As

Publication number Publication date
JP2013527164A (ja) 2013-06-27
WO2011135426A1 (en) 2011-11-03
EP2563346A1 (en) 2013-03-06
US20180078549A1 (en) 2018-03-22
EP2563346A4 (en) 2013-10-23
US20110263606A1 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
US20110263606A1 (en) Solid oral dosage forms comprising tadalafil
US9717682B2 (en) Solid oral film dosage forms and methods for making same
US12156937B2 (en) Oral film formulation for modulating absorption profile
US10610528B2 (en) Solid oral film dosage forms and methods for making same
JP2017520508A (ja) タダラフィルを含む口腔内崩壊フィルム製剤およびその製造方法
TWI835118B (zh) 布瑞哌唑口溶膜組合物、其製備方法及用途
EP4076380B1 (en) Transmucosal therapeutic system containing agomelatine
US20180110724A1 (en) Film dosage form with multimodal and particle size distributions
JP2024522779A (ja) マクロライドの非ナノ粒子適用形態
EP4076381B1 (en) Transmucosal therapeutic system containing agomelatine
Saeed et al. Effect of natural/synthetic polymers and super disintegrants on the formulation of zafirlukast fast dissolving film
CZ2016570A3 (cs) Stabilní kompozice ODF obsahující těžce rozpustné terapeutické činidlo
WO2024220974A1 (en) Rimegepant fast-dissolving films for oral administration
WO2024207637A1 (zh) 一种雷美替胺舌下膜剂及其制备方法
JP2012031164A (ja) フィルム状製剤
KR102153894B1 (ko) 온단세트론 또는 이의 염을 함유하는 구강 붕해형 필름 제제 및 이의 제조방법
AU2021102780A4 (en) A process to formulate chitosan oligosaccharide based mucoadhesive patch for drug delivery
Ahmed Nanosuspension-Based Repaglinide Fast-Dissolving Buccal Film for Dissolution Enhancement
JP2026503785A (ja) 免疫疾患もしくは障害の予防または治療方法に使用するためのマクロライド
WO2023170184A1 (en) Transmucosal therapeutic system containing a macrolide immunosuppressant
HK40082930A (en) Transmucosal therapeutic system containing agomelatine
HK40082930B (en) Transmucosal therapeutic system containing agomelatine
WO2015186929A1 (ko) 타달라필을 함유하는 구강 붕해 필름 및 이의 제조방법

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160126

FZDE Dead

Effective date: 20200928